These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1310746)

  • 1. Secondary screening system for preclinical testing of human lung cancer therapies.
    Mulvin DW; Howard RB; Mitchell DH; Noker PE; Kruse CA; Chu HD; Bunn PA; Johnston MR
    J Natl Cancer Inst; 1992 Jan; 84(1):31-7. PubMed ID: 1310746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related doxorubicin effect in an orthotopic secondary lung cancer screen.
    Cowen ME; Howard RB; Noker PE; Zeligman BE; Mulvin DW; Marcell T; Johnston MR
    J Surg Res; 1994 Apr; 56(4):295-301. PubMed ID: 8152221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irradiated nude rat model for orthotopic human lung cancers.
    Howard RB; Chu H; Zeligman BE; Marcell T; Bunn PA; McLemore TL; Mulvin DW; Cowen ME; Johnston MR
    Cancer Res; 1991 Jun; 51(12):3274-80. PubMed ID: 2040002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer cells with interleukin-2: dose toxicity and localization in isolated perfused rat lungs.
    Mulvin DW; Kruse CA; Mitchell DH; Marcell T; James GT; Johnston MR
    Mol Biother; 1990 Mar; 2(1):38-43. PubMed ID: 2334537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement of an orthotopic lung cancer model in the nude rat.
    March TH; Marron-Terada PG; Belinsky SA
    Vet Pathol; 2001 Sep; 38(5):483-90. PubMed ID: 11572555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice bearing lung metastases.
    Mandruzzato S; Rosato A; Bronte V; Zanovello P; Amboldi N; Ballinari D; Collavo D
    Cancer Res; 1994 Feb; 54(4):1016-20. PubMed ID: 8313356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats.
    Gaspar MM; Radomska A; Gobbo OL; Bakowsky U; Radomski MW; Ehrhardt C
    J Aerosol Med Pulm Drug Deliv; 2012 Dec; 25(6):310-8. PubMed ID: 22857016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-human lung giant cell cancer (PG) effect of human LAK cells in vitro and in nude mice].
    Deng HY
    Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):258-60. PubMed ID: 2272258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of free and liposomal doxorubicin after isolated lung perfusion in a sarcoma model.
    Yan H; Cheng C; Haouala A; Krueger T; Ballini JP; Peters S; Decosterd LA; Letovanec I; Ris HB; Andrejevic-Blant S
    Ann Thorac Surg; 2008 Apr; 85(4):1225-32. PubMed ID: 18355500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
    Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat.
    Howard RB; Mullen JB; Pagura ME; Johnston MR
    Clin Exp Metastasis; 1999 Mar; 17(2):157-62. PubMed ID: 10411108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
    Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
    Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN; Khoo NK; Lala PK
    Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated single-lung perfusion: a study of the optimal perfusate and other pharmacokinetic factors.
    Weksler B; Ng B; Lenert JT; Burt ME
    Ann Thorac Surg; 1995 Sep; 60(3):624-9. PubMed ID: 7545890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.